Asparkam - instructions for use, dose, side effects, contraindications

Potassium asparaginate 175 mg, magnesium asparaginate 175 mg, obtained by prescription DL-aspargic acid in terms of 100% - 258.4 mg, magnesium oxide in terms of 100% content - 19.6 mg, potassium hydroxide in terms of 100% content - 54.5 mg;

Excipients: calcium stearate - 5 mg, corn starch - 135 mg, talc - 10 mg. Weight of the tablet is 500 mg.

Description:

Tablets of white color, with a smooth surface, flat-cylindrical, with a risk, a round shape with a specific odor.

Pharmacotherapeutic group:Potassium and magnesium preparation

ATX: & nbsp

A.12.C.X Preparations of other minerals

Pharmacodynamics:

Aspartame refers to drugs that regulate metabolic processes. The mechanism of action is associated with the role of aspartate to transfer magnesium and potassium ions to intracellular space and their participation in metabolic processes. Asparki eliminates electrolyte imbalance, magnesium and potassium deficiency, reduces excitability and myocardial conductivity (moderate antiarrhythmic effect), improves myocardial metabolism and coronary circulation, and also reduces myocardial sensitivity to cardiac glycosides and the manifestation of their toxicity. Ions Mg²⁺(magnesium) activates Na⁺(sodium) K⁺(potassium) -ATPase. In connection with this, the intracellular ion concentration decreases Na⁺ (sodium) and the intake of ions K⁺ (potassium) into the cells. When the concentration of ions decreases Na⁺ Inside the cell, ion exchange is inhibited Na⁺(sodium) and Ca²⁺(calcium) in the smooth muscles of the vessels, which leads to their relaxation. Iones K⁺(potassium) stimulate the synthesis of ATP (adenosine triphosphate), glycogen, proteins, acetylcholine. Iones K⁺(potassium) and Mg²⁺ (magnesium) support the polarization of cell membranes. Aspartate is a carrier of ions K⁺ (potassium) and Mg²⁺ (magnesium) and promotes their entry into the intracellular space. Getting into the cell, aspartate is also involved in metabolic processes, promotes the synthesis of amino acids, amino sugars, nucleotides, nitrogen-containing lipids, corrects the disturbance of energy metabolism ischemic myocardium.

Pharmacokinetics:

Quickly and completely absorbed when taken orally, excreted mainly by the kidneys. The concentration of potassium and magnesium in the blood reaches a maximum after 1-2 hours after taking the drug. From the blood, the drug enters the cardiomyocytes in the form of K ions⁺(potassium), Mg²⁺(magnesium) and aspartate and is included in the cellular metabolism.

Indications:

Replenishment of potassium and magnesium deficiency in the complex therapy for coronary heart disease (including acute myocardial infarction), chronic heart failure, heart rhythm disturbances (including against the background of cardiac glycosides overdose).

Contraindications:

Hypersensitivity to the drug components, acute and chronic renal failure, Addison's disease, hyperkalemia, hypermagnesia, atrioventricular blockade II-III degree, cardiogenic shock (arterial pressure <90 mm Hg), insufficiency of the adrenal cortex, hemolysis, severe myasthenia gravis, metabolic disorders of amino acids.

Pregnancy and lactation:

Data on the adverse effects of the drug during pregnancy or lactation are not available. However, the use of the drug is possible if, in the opinion of the doctor, the expected benefit for a woman exceeds the risk for the fetus or child.

Dosing and Administration:

Asparkam, tablets, are taken orally after a meal.

Adults prescribe 1-2 tablets 3 times a day.

The course of treatment is determined by the doctor depending on the nature and course of the disease.

The average course of treatment is 3-4 weeks.

Side effects:

From the digestive tract: nausea, vomiting, diarrhea, abdominal pain, a feeling of discomfort or burning in the epigastric region, gastrointestinal bleeding, ulcers of the mucosa of the digestive tract, dryness of the oral mucosa;

from the cardiovascular system: disturbance of myocardial conductivity, lowering of arterial pressure, AV-blockade;

from the central and peripheral nervous system: paresthesia, hyporeflexia, convulsions;

allergic reactions: skin rash, itching, redness of the skin of the face;

from the respiratory system: possible respiratory depression (due to hypermagnesia);

Other: feeling of heat.

Overdose:

At the moment, cases of overdose are not registered. Overdose may cause symptoms of hyperkalemia (nausea, vomiting, diarrhea, abdominal pain, metallic taste in the mouth, bradycardia, weakness, disorientation,muscle paralysis, paresthesia of the extremities) and hypermagnesia (reddening of the facial skin, thirst, arterial hypotension, hyporeflexia, violation of neuromuscular transmission, respiratory depression, arrhythmia, convulsions). On the electrocardiogram, an increase in the height of the tooth T, a decrease in the amplitude of the tooth P, an expansion of the complex QRS.

Treatment: withdrawal of the drug, symptomatic therapy (intravenous calcium chloride solution in a dose of 100 mg per minute), if necessary - hemodialysis.

Interaction:

In connection with the presence of potassium ions in the formulation of Asparkam with potassium-sparing diuretics, ACE inhibitors (angiotensin-converting enzyme), beta-adrenoblockers, cyclosporine, nonsteroidal anti-inflammatory drugs and heparin increases the risk of hyperkalemia (necessary control of potassium levels in the blood plasma) and intensifies the depressing effect on intestinal motility.

The drug inhibits the absorption of medicinal forms for oral administration of tetracycline, iron salts and sodium fluoride (it is necessary to adhere to a 3-hour interval between doses).

Asparki intensifies the effect of drugs that stimulate trophic processes in the myocardium; prevents the development of hypokalemia caused by the use of sialuric drugs, glucocorticosteroids, cardiac glycosides. Aspartame reduces the cardiotoxic effect of cardiac glycosides.

When used simultaneously with depolarizing muscle relaxants, neuromuscular blockade is intensified, with agents for anesthesia (ketamine, hexanal, fluorotane, etc.) - the central nervous system is depressed.

Asparks can reduce the effectiveness of neomycin, polymyxin B, tetracycline and streptomycin.

Calcitriol increases the magnesium content of the plasma. Under the influence of potassium preparations, undesirable effects of cardiac glycosides decrease.

Astringent and enveloping agents reduce absorption from the gastrointestinal tract (it is necessary to observe the interval of 3 hours when taking other medicines).

Special instructions:

With prolonged use of the drug, it is necessary to monitor the content of potassium and magnesium in the blood, and regular monitoring of electrolyte hemostasis and ECG (electrocardiogram) data is necessary.

Effect on the ability to drive transp. cf.and fur:

The effect of the drug on the ability to drive vehicles has not been studied.

Form release / dosage:Pills.

Packaging:

50 tablets per blister.

Each blister, together with instructions for medical use, is put in a pack of cardboard.

Storage conditions:

In a dry place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after expiration date indicated on the package

Terms of leave from pharmacies:On prescription

Registration number:П N011730 / 01

Date of registration:23.04.2012

Expiration Date:Unlimited

The owner of the registration certificate:GALICHFARM, PAO GALICHFARM, PAO Ukraine

Manufacturer: & nbsp

GALICHFARM, PAO Ukraine

Information update date: & nbsp27.09.2017

Illustrated instructions

Instructions

Aspark (Asparcam)